<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943851</url>
  </required_header>
  <id_info>
    <org_study_id>116183</org_study_id>
    <secondary_id>2013-000445-39</secondary_id>
    <nct_id>NCT01943851</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies</brief_title>
  <official_title>A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label repeat dose, multicenter, 2-part study to determine the maximum&#xD;
      tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily&#xD;
      (QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2&#xD;
      dose (RP2D) based on the safety, PK, and PD profiles observed after oral administration of&#xD;
      GSK525762. Eligible subjects with select relapsed refractory hematological malignancies&#xD;
      (acute myeloid leukemia [AML], non-Hodgkin's Lymphoma [NHL]and multiple myeloma [MM]), will&#xD;
      be enrolled in the QD and/or BID dosing cohorts until a MTD is established. Subjects may&#xD;
      continue treatment in the study until disease progression, unacceptable toxicity, or&#xD;
      withdrawal of consent. . Upon determination of the MTD, twice daily (BID) dosing cohorts may&#xD;
      be opened to collect additional safety data and evaluate the preliminary efficacy of&#xD;
      GSK525762 administered BID. Part 2 will explore clinical activity at the MTD or RP2D;&#xD;
      separate expansion cohorts will be planned for acute myeloid leukemia (AML), non-Hodgkin's&#xD;
      Lymphoma (NHL, including an exploratory sub-cohort of subjects with myc and B-Cell Leukemia&#xD;
      (BCL)2 and/or BCL6 rearrangements/overexpression [double- and triple-hit lymphoma]), and&#xD;
      multiple myeloma (MM). This is the first study of this agent to be conducted in subjects with&#xD;
      these relapsed and/or refractory hematological malignancies for which no standard therapies&#xD;
      are anticipated to result in a durable remission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2014</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD)</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>An event was considered DLT if it occurred within first 3weeks of treatment &amp; met one of following criteria:unless it was clearly established that event is unrelated to treatment:Grade4 neutropenia persisting for &gt;=7 days/febrile neutropenia not responding to treatment within 24hours, Grade4 thrombocytopenia lasting more than 7day &amp; not responding to transfusions/Grade3 thrombocytopenia associated with bleeding (&gt;10milliliter [mL]), Drug-related Grade 3/4 non-hematologic toxicity as described in National Cancer Institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 4.0, Drug-related Grade2 non-hematological toxicity, Grade2 Troponin T elevation(central laboratory&gt;Upper Limit of Normal[ULN]),measured on two separate occasions within 48 hours, Treatment delay of 14 days/greater due to unresolved drug-related toxicity,ALT&gt;=3xULN+bilirubin&gt;=2xULN(&gt;35% direct)/Alanine aminotransferase(ALT) between 3-5xULN with bilirubin&lt;2xULN but with hepatitis symptom/rash/ALT&gt;=5xULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Dose Reductions</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Number of participants with dose reductions due to any reason is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Any Dose Interruptions or Delays</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Number of participants with any dose interruptions/ delays is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, prothrombin international normalized ratio (Pro. INR), albumin, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, triglycerides, alkaline phosphatase (ALP). Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Grade Change From Baseline in Hematology Parameters</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Urine samples were collected to assess glucose, ketones, occult blood, urine protein, and monoclonal protein (monoclonal pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low &lt;60 beats per minute [bpm] and high &gt;100 bpm); For body temperature (&lt;=35 degrees Celsius or &gt;=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category. Participants were counted twice if the participant had values that changed &quot;To Low&quot; and &quot;To High&quot;, so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (&lt;=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (&gt;=160 mmHg). For DBP: Grade 0 (&lt;=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (&gt;=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective Response Rate (ORR) (MDS Cohort)</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>ORR for MDS cohort is defined as the percentage of participants achieving Complete Response (CR), Marrow CR, CRp (as per CR but platelet count &lt;100 x 10^9 cells/Liter[L]), CRi (as per CR but platelet count &lt;100 x 10^9cells/L or neutrophil count &lt;1 x 10^9 cells/L), or Partial Response (PR) per response criteria. Complete response is defined as bone marrow &lt;=5% myeloblasts with normal maturation of all cell lines, with hemoglobin concentration of &gt;=11 grams per deciliter (g/dL), absolute neutrophil count &gt;=1 x 10^9 cells/L, platelet count &gt;=100x10^9 cells/L and 0% blasts in the peripheral blood. Marrow CR is defined as Bone marrow &lt;=5% myeloblasts and decrease by &gt;=50% over pre-treatment. Objective response rate was determined by the investigator according to international myeloma working group (IMWG) response criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective Response Rate Lasting at Least 4 Months (ORR4) (CTCL Cohorts)</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>ORR4 for CTCL cohorts is defined as the percentage of participants that have achieved a CR or PR lasting at least 4 months per global response criteria and the modified severity weighted assessment tool (mSWAT). ORR4 and 95% exact confidence interval is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Overall Response Rate (ORR)- Investigator Assessment</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>ORR is defined as the percentage of participants achieving stringent complete response (sCR), very good partial response (VGPR), partial response (PR) or minimal response (MR) for multiple myeloma (MM); CR or PR for Non-Hodgkin's Lymphoma (NHL); CR, CRp, CRi or PR for Acute Myeloid Leukemia (AML); CR, MR or PR for Myelodysplastic Syndrome (MDS) using the International Working Group (IWG) response criteria and IWG response criteria in myelodysplasia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0-24]) and AUC Extrapolated to Infinity (AUC[0-inf]) of GSK525762 Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC(0-24) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK525762 Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. AUC(0-24) represents AUC(0-tau) for repeat dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) and Minimum Plasma Concentration (Cmin) of GSK525762 Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax and Cmin of GSK525762 Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Trough Concentration (Ctau) of GSK525762 Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose on Days 4, 6 and 7</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time of Maximum Concentration (Tmax) of GSK525762 Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of GSK525762 Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Terminal Half Life (T1/2) of GSK525762 Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: T1/2 of GSK525762 Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time Invariance (RS) of GSK525762</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Accumulation Ratio (RO) of GSK525762</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Clearance (CL/F) of GSK525762 After Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Clearance (CL/F) of GSK525762 After Repeat Dose Administration</measure>
    <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Repeat Dose Administration</measure>
    <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC(0-24) and AUC[0-inf] of GSK3529246 (Active Metabolite) Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for PK analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC(0-24) and AUC(0-tau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762. AUC(0-tau) is AUC(0-24) for repeat dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Trough Concentration (Ctau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose on Days 4, 6 and 7</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of GSK3529246 (Active Metabolite) Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time Invariance (RS) of GSK3529246 (Active Metabolite)</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Accumulation Ratio (RO) of GSK3529246 (Active Metabolite)</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. PK parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration</measure>
    <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</measure>
    <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
    <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in Skindex-29 Domain Scores (Emotional, Functioning and Symptoms Score) for CTCL Cohort</measure>
    <time_frame>Baseline (pre-dose Week1 Day1) and Week 3, Week 7, Week 10, Week 16 and Week 24</time_frame>
    <description>The effects of treatment on disease-related symptoms/quality of life was assessed using the Skindex-29 Questionnaire, which inquires about how often (Never, Rarely, Sometimes, Often, All the time) during the previous 4 weeks the participant experienced the effect described in each of 29 items divided into 3 domains: Emotional (10 items), Symptoms (7 items) and Functioning (12 items). Responses to each item are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex-29 scores were reported as three individual domain scale scores; a scale score is the mean of a participant's responses to items in a given domain. Each domain score ranges from 0 (no effect) to 100 (effect experienced all the time), higher score implies higher impact of skin disease. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is defined is post-dose visit value minus Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Non-serious AEs and SAEs and AELDs</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Dose Reductions</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Number of participants with dose reductions due to any reason is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Dose Interruptions/Delays</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Number of participants with any dose interruptions or delays is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, Prothrombin international normalized ratio (Pro. INR), albumin, amylase, ALT, AST, bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, Triglycerides, ALP. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Grade Change From Baseline in Hematology Parameters</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Urine samples were collected to assess glucose, ketones, occult blood, urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low &lt;60 beats per minute [bpm] and high &gt;100 bpm); For body temperature (&lt;=35 degrees Celsius or &gt;=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category. Participants were counted twice if the participant had values that changed &quot;To Low&quot; and &quot;To High&quot;, so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: DBP and SBP</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (&lt;=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (&gt;=160 mmHg). For DBP: Grade 0 (&lt;=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (&gt;=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression Free Survival (PFS)</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>PFS defined as interval of time(in months) between date of first dose &amp; earlier of date of disease progression &amp; date of death due to any cause.Progression is participants(pt's)with MDS &amp; with &lt;5% blasts:&gt;=50% increase in blasts to&gt;5% blasts/pt's with 5-10% blasts:&gt;=50% increase to &gt;10% blasts, for pt's with 10-20% blasts:&gt;=50% increase to &gt;20% blasts,for pt's with 20%-30% blasts:&gt;=50% increase to &gt;30% blasts, for CTCL progression is &gt;=25% increase in skin disease from Baseline/new tumors (T3[1 or more tumors(&gt;=1cm diameter]) in pt's with T1(Limited patches,papules&amp;/or plaques covering &lt;10% of the skin surface;may further stratify into T1a [patch only] versus T1b [plaque+-patch]),T2(Patches,papules/plaques covering &gt;=10% of skin surface;may further stratify into T2a[patch only]versus T2b [plaque+-patch]) orT4(Confluence of erythema covering &gt;=80% body surface area) only skin disease/loss of response in those with CR/PR, increase of skin score of &gt; sum of nadir +50% Baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of Response (DOR)</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Duration of response is defined as the time from the first documented evidence response (CR or PR lasting 4 months for CTCL; and CR, marrow CR, CRp, Cri or PR for MDS) until the first documented disease progression or death due to any cause. Median and inter-quartile range (first quartile and third quartile) of duration of response are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall Survival (OS)</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>OS is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Part 2: Time to Progression (TTP) for Participants With MM</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Time to Progression was planned to be analyzed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1: Changes in Cardiac QT Duration Corrected for Heart Rate by Fridericia's Formula (QTcF) and Other Safety Parameters in Relation to GSK525762 PK Concentrations</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Changes in QTcF and other safety parameters in relation to GSK525762 PK concentrations was planned to be analyzed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1: Number of Participants With Dose /Exposure Markers Related Change in Molecular Markers in Tumor Tissue and/or Peripheral Blood Samples</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Number of participants with dose /exposure markers related change in molecular markers (e.g. gene transcription and/or expression of proteins regulated by Bromodomain [BRD] proteins) in tumor tissue and/or peripheral blood samples were planned to be analyzed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Plasma Concentrations of GSK525762 in Relationship With Safety and Efficacy Parameters Derived From Pharmacokinetic/Pharmacodynamic (PK/PD) Model</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Plasma concentrations of GSK525762 in relationship with safety and efficacy parameters derived from PK/PD model was planned to be analyzed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Number of Participants With Dose /Exposure Markers Related Change in Molecular Markers in Tumor Tissue and/or Peripheral Blood Samples</measure>
    <time_frame>Up to 36.4 weeks</time_frame>
    <description>Number of participants with dose /exposure markers related change in molecular markers (e.g. gene transcription and/or expression of proteins regulated by Bromodomain proteins) in tumor tissue and/or peripheral blood samples were planned to be analyzed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 1: Overall Survival (OS)</measure>
    <time_frame>Up to 86.9 weeks</time_frame>
    <description>Overall survival (defined as the interval of time in months between the date of first dose and the date of death due to any cause) was planned to be analyzed.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1: GSK525762 QD Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: GSK525762 BID Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GSK525762 dose expansion cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK525762</intervention_name>
    <description>GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.</description>
    <arm_group_label>Part 1: GSK525762 BID Cohort</arm_group_label>
    <arm_group_label>Part 1: GSK525762 QD Cohort</arm_group_label>
    <arm_group_label>Part 2: GSK525762 dose expansion cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  Males and females 18 years old or older.&#xD;
&#xD;
          -  In Part 1 and, Part 2, subjects must have AML, MM, or NHL. Subjects with AML, are&#xD;
             eligible if they â€¢ have relapsed and/or refractory disease, OR are&gt;=65 years of age&#xD;
             and not candidates for or have refused standard chemotherapy. Subjects with multiple&#xD;
             myeloma are eligible if they have progressed despite therapy with an alkylating agent,&#xD;
             proteasome inhibitor, and immunomodulatory agent, either as individual regimens or in&#xD;
             combination. Subjects with NHL are eligible if they have received at least two prior&#xD;
             lines of systemic therapy, including at least one line of immunochemotherapy with an&#xD;
             anti-CD20 antibody (if their tumor expresses CD20).&#xD;
&#xD;
        In Part 2, the NHL cohort will separately enrol subjects with double- and triple hit&#xD;
        lymphoma, so that a minimum of 10 subjects with this subset of disease will be enrolled. To&#xD;
        be eligible for this sub-cohort, tumor sample from the subject must demonstrate&#xD;
        rearrangement and/or overexpression of MYC and either BCL2 and/or BCL6 genes. Evaluation of&#xD;
        double- or triple-hit status may be performed via appropriate local testing, and the&#xD;
        determination of double- or triple-hit diagnosis will be at the discretion of the&#xD;
        investigator and GSK Medical Monitor.&#xD;
&#xD;
          -  Subjects with a prior history of stem cell transplant (autologous and/or allogeneic)&#xD;
             are allowed if&#xD;
&#xD;
               -  At least 3 months has elapsed from the time of transplant and&#xD;
&#xD;
               -  the subject has recovered from transplant-associated toxicities prior to the&#xD;
                  first dose of GSK525762, and For subjects with a prior history of allogeneic&#xD;
                  transplant,&#xD;
&#xD;
               -  the subject has been off systemic immunosuppressive medications (including but&#xD;
                  not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or&#xD;
                  corticosteroids) for at least 1 month prior to the first dose of GSK525762.&#xD;
                  Topical steroids are permitted&#xD;
&#xD;
               -  there are no signs or symptoms of graft versus host disease, other than Grade 1&#xD;
                  skin involvement.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt;=1.&#xD;
&#xD;
          -  Subject must be stable enough to be expected to complete dosing through the DLT&#xD;
             observation period as assessed by the investigator.&#xD;
&#xD;
          -  Able to swallow and retain orally administered medication and does not have any&#xD;
             clinically significant gastrointestinal abnormalities that may alter absorption such&#xD;
             as malabsorption syndrome or major resection of the stomach or bowels.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases,&#xD;
             a blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40&#xD;
             milli-International units per milliliter and estradiol &lt; 40 picograms per milliliter&#xD;
             (&lt; 140 picomole per liter) is confirmatory]. Females on hormone replacement therapy&#xD;
             (HRT) and whose menopausal status is in doubt will be required to use one of the&#xD;
             contraception methods defined in protocol if they wish to continue their HRT during&#xD;
             the study. Otherwise, they must discontinue HRT to allow confirmation of&#xD;
             post-menopausal status prior to study enrolment. For most forms of HRT, at least two&#xD;
             to four weeks will elapse between the cessation of therapy and the blood draw; this&#xD;
             interval depends on the type and dosage of HRT. Following confirmation of their&#xD;
             post-menopausal status, they can resume use of HRT during the study without use of a&#xD;
             contraceptive method; Child-bearing potential and agrees to use one of the&#xD;
             contraception methods for an appropriate period of time (as determined by the product&#xD;
             label or investigator) prior to the start of dosing to sufficiently minimize the risk&#xD;
             of pregnancy at that point. Female subjects must agree to use contraception until at&#xD;
             least 7 months after the last dose of study medication; Negative serum pregnancy test&#xD;
             &lt;= 7 days prior to first study drug dose; Female subjects who are lactating must&#xD;
             discontinue nursing prior to the first dose of study treatment and must refrain from&#xD;
             nursing throughout the treatment period and for 5 half-lives of GSK525762 or at least&#xD;
             28 days (whichever is longer) following the last dose of study treatment.&#xD;
&#xD;
          -  Male subjects must agree to use one of the methods of contraception specified. This&#xD;
             method must be used from the time of the first dose of study medication until 16 weeks&#xD;
             after the last dose of study medication. In addition, male subjects whose partners are&#xD;
             or become pregnant must continue to use condoms for 7 days after stopping study&#xD;
             medications.&#xD;
&#xD;
          -  Adequate organ system function.&#xD;
&#xD;
          -  Ability to comply with dietary and tobacco/alcohol abstinence requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Haematological malignancy associated with human immunodeficiency virus (HIV) infection&#xD;
             or solid organ transplant or history of known Hepatitis B Antigen or positive&#xD;
             Hepatitis C antibody (confirmed by Recombinant ImmunoBlot Assay [RIBA], if available&#xD;
             or alternately confirmed by Hepatitis C Virus [HCV] Ribonucleic acid [RNA]).&#xD;
&#xD;
          -  History or concurrent malignancy of solid tumours, except for below. Exception:&#xD;
             Subjects who have been disease-free for 5 years, or subjects with a history of&#xD;
             completely resected non-melanoma skin cancer or successfully treated in situ carcinoma&#xD;
             are eligible. Subjects with second malignancies that are indolent or definitively&#xD;
             treated may be enrolled even if less than 5 years have elapsed since treatment.&#xD;
             Consult the GSK Medical Monitor if unsure whether second malignancies meet&#xD;
             requirements specified above.&#xD;
&#xD;
          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy,&#xD;
             biologic therapy, hormonal therapy, surgery, and/or tumour embolization).The following&#xD;
             are allowed: Hydroxyurea for proliferative disease, Corticosteroids, Use of&#xD;
             hematopoetic growth factors is permitted at the discretion of the investigator&#xD;
             according to published guidelines (e.g., National Comprehensive Cancer Network (NCCN),&#xD;
             American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH),&#xD;
             etc.). The following are NOT allowed: Investigational anti cancer drug within 2 weeks&#xD;
             prior to the first dose of GSK525762; Major surgery, radiotherapy, or immunotherapy&#xD;
             within 4 weeks of GSK525762 Chemotherapy regimens with delayed toxicity within the&#xD;
             last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with&#xD;
             limited potential for delayed toxicity within the last 2 weeks.&#xD;
&#xD;
        Nitrosourea or mitomycin C within the last 6 weeks&#xD;
&#xD;
          -  Evidence of severe of uncontrolled infection.&#xD;
&#xD;
          -  Use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days&#xD;
             prior to the first dose of GSK525762. Low dose (prophylactic) low molecular weight&#xD;
             heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with&#xD;
             local institutional practices, as appropriate.&#xD;
&#xD;
          -  Current use of a prohibited medication or requires any of these medications during&#xD;
             treatment with the investigational drugs. This includes excluding current medications&#xD;
             known or suspected to be associated QT prolongation. In addition, any subject who is&#xD;
             expected to require a QT prolonging medication while on trial should not be enrolled.&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated&#xD;
             respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding&#xD;
             episodes). Any serious and/or unstable pre-existing medical (aside from malignancy&#xD;
             exception above), psychiatric disorder, or other conditions that could interfere with&#xD;
             subject's safety, obtaining informed consent or compliance to the study procedures, in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
          -  Symptomatic or untreated Central nervous system (CNS) disease, Subjects with a history&#xD;
             of CNS disease (leukemia, lymphoma or myeloma) are permitted to enrol if they have&#xD;
             previously received appropriate therapy and CNS remission has been documented. Subject&#xD;
             with primary CNS lymphoma (defined as isolated CNS lymphoma without systemic&#xD;
             involvement) are excluded from study.&#xD;
&#xD;
          -  Cardiac abnormalities as evidenced by any of the following: History or current&#xD;
             clinically significant uncontrolled arrhythmias or hypertension; Clinically&#xD;
             significant conduction abnormalities or arrhythmias, subjects with Bundle Branch&#xD;
             Block; Presence of cardiac pacemaker; History or evidence of current &gt;=Class II&#xD;
             congestive heart failure as defined by New York Heart Association (NYHA); History of&#xD;
             acute coronary syndromes (including unstable angina and myocardial infarction),&#xD;
             coronary angioplasty, or stenting within the past 3 months.&#xD;
&#xD;
          -  Any of the following ECG findings or assessments including: Baseline QTcF interval&#xD;
             &gt;=450 milliseconds; Clinically significant ECG assessments should be reviewed by the&#xD;
             site cardiologist prior to study entry.&#xD;
&#xD;
          -  GSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed&#xD;
             hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related&#xD;
             to the investigational drug.&#xD;
&#xD;
          -  Evidence of hemoptysis within the last 7 days.&#xD;
&#xD;
          -  History of major gastrointestinal bleeding within the last 3 months or any evidence of&#xD;
             active gastrointestinal bleeding excludes the subject.&#xD;
&#xD;
          -  Presence of gastrointestinal disease that would significantly affect compound&#xD;
             absorption.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, Dhar A, Karpinich N, Tian L, Tyler DS, MacPherson L, Shi J, Pinnawala N, Yew Fong C, Papenfuss AT, Grimmond SM, Dawson SJ, Allan RS, Kruger RG, Vakoc CR, Goode DL, Naik SH, Gilan O, Lam EYN, Marine JC, Prinjha RK, Dawson MA. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nat Commun. 2019 Jun 20;10(1):2723. doi: 10.1038/s41467-019-10652-9.</citation>
    <PMID>31222014</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <results_first_submitted>April 26, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>BET inhibitor</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Myelodysplastic syndromes</keyword>
  <keyword>Oncology</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>GSK525762</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT01943851/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT01943851/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label repeat dose, multicenter study to investigate the safety, pharmacokinetics (PK), pharmacodynamics and clinical activity of GSK525762 in participants with relapsed, refractory hematologic malignancies. The study was conducted in 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion)</recruitment_details>
      <pre_assignment_details>A total of 111 participants were enrolled (87 participants in Part 1 and 24 participants in Part 2) across the study centers in Australia, Spain, Great Britain, South Korea and United State of America (USA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: GSK525762 5 mg QD</title>
          <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: GSK525762 10 mg QD</title>
          <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: GSK525762 20 mg QD</title>
          <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: GSK525762 30 mg QD MM</title>
          <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: GSK525762 40 mg QD</title>
          <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: GSK525762 40 mg QD MM</title>
          <description>Participants with MM were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="P7">
          <title>Part 1: GSK525762 60 mg QD AML</title>
          <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="P8">
          <title>Part 1: GSK525762 60 mg QD NHL</title>
          <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="P9">
          <title>Part 1: GSK525762 60 mg QD MM</title>
          <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="P10">
          <title>Part 1: GSK525762 75 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
        </group>
        <group group_id="P11">
          <title>Part 1: GSK525762 80 mg QD</title>
          <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="P12">
          <title>Part 1: GSK525762 80 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="P13">
          <title>Part 1: GSK525762 80 mg QD NHL</title>
          <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="P14">
          <title>Part 1: GSK525762 100 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
        </group>
        <group group_id="P15">
          <title>Part 1: GSK525762 120 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
        </group>
        <group group_id="P16">
          <title>Part 2: GSK525762 60 mg QD CTCL</title>
          <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="P17">
          <title>Part 2: GSK525762 75 mg QD MDS</title>
          <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762.</description>
        </group>
        <group group_id="P18">
          <title>Part 2: GSK525762 80 mg QD CTCL</title>
          <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 (Up to 86.9 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="18"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="16"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="16"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="15"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2 (Up to 36.4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="16"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="13"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>NA indicates, Data not presented due to participant confidentiality and privacy concerns</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: GSK525762 5 mg QD</title>
          <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: GSK525762 10 mg QD</title>
          <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: GSK525762 20 mg QD</title>
          <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: GSK525762 30 mg QD MM</title>
          <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: GSK525762 40 mg QD</title>
          <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: GSK525762 40 mg QD MM</title>
          <description>Participants with MM were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="B7">
          <title>Part 1: GSK525762 60 mg QD AML</title>
          <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="B8">
          <title>Part 1: GSK525762 60 mg QD NHL</title>
          <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="B9">
          <title>Part 1: GSK525762 60 mg QD MM</title>
          <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="B10">
          <title>Part 1: GSK525762 75 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
        </group>
        <group group_id="B11">
          <title>Part 1: GSK525762 80 mg QD</title>
          <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="B12">
          <title>Part 1: GSK525762 80 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="B13">
          <title>Part 1: GSK525762 80 mg QD NHL</title>
          <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="B14">
          <title>Part 1: GSK525762 100 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
        </group>
        <group group_id="B15">
          <title>Part 1: GSK525762 120 mg QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
        </group>
        <group group_id="B16">
          <title>Part 2: GSK525762 60 mg QD CTCL</title>
          <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="B17">
          <title>Part 2: GSK525762 75 mg QD MDS</title>
          <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762.</description>
        </group>
        <group group_id="B18">
          <title>Part 2: GSK525762 80 mg QD CTCL</title>
          <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="18"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="1"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="7"/>
            <count group_id="B14" value="16"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="7"/>
            <count group_id="B17" value="16"/>
            <count group_id="B18" value="1"/>
            <count group_id="B19" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65-74 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="9"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;74 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="10"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="10"/>
                    <measurement group_id="B18" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Japanese Heritage(H)/eastAsian (H)/Southeast Asian (H)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African american</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Native hawaiian or other pacific islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="NA">NA indicates, Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="14"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="15"/>
                    <measurement group_id="B18" value="NA">NA indicates, Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian and native hawaiian or other pacific islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="NA">NA indicates, Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B2" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B3" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="NA">Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="NA">NA indicates, Data not presented due to patient confidentiality and privacy concerns</measurement>
                    <measurement group_id="B19" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population consists of all participants that received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.</description>
          <population>All Treated Population consists of all participants that received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="16"/>
                    <measurement group_id="O15" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="14"/>
                    <measurement group_id="O15" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AELD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</title>
        <description>An event was considered DLT if it occurred within first 3weeks of treatment &amp; met one of following criteria:unless it was clearly established that event is unrelated to treatment:Grade4 neutropenia persisting for &gt;=7 days/febrile neutropenia not responding to treatment within 24hours, Grade4 thrombocytopenia lasting more than 7day &amp; not responding to transfusions/Grade3 thrombocytopenia associated with bleeding (&gt;10milliliter [mL]), Drug-related Grade 3/4 non-hematologic toxicity as described in National Cancer Institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 4.0, Drug-related Grade2 non-hematological toxicity, Grade2 Troponin T elevation(central laboratory&gt;Upper Limit of Normal[ULN]),measured on two separate occasions within 48 hours, Treatment delay of 14 days/greater due to unresolved drug-related toxicity,ALT&gt;=3xULN+bilirubin&gt;=2xULN(&gt;35% direct)/Alanine aminotransferase(ALT) between 3-5xULN with bilirubin&lt;2xULN but with hepatitis symptom/rash/ALT&gt;=5xULN.</description>
        <time_frame>Up to 3 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</title>
          <description>An event was considered DLT if it occurred within first 3weeks of treatment &amp; met one of following criteria:unless it was clearly established that event is unrelated to treatment:Grade4 neutropenia persisting for &gt;=7 days/febrile neutropenia not responding to treatment within 24hours, Grade4 thrombocytopenia lasting more than 7day &amp; not responding to transfusions/Grade3 thrombocytopenia associated with bleeding (&gt;10milliliter [mL]), Drug-related Grade 3/4 non-hematologic toxicity as described in National Cancer Institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 4.0, Drug-related Grade2 non-hematological toxicity, Grade2 Troponin T elevation(central laboratory&gt;Upper Limit of Normal[ULN]),measured on two separate occasions within 48 hours, Treatment delay of 14 days/greater due to unresolved drug-related toxicity,ALT&gt;=3xULN+bilirubin&gt;=2xULN(&gt;35% direct)/Alanine aminotransferase(ALT) between 3-5xULN with bilirubin&lt;2xULN but with hepatitis symptom/rash/ALT&gt;=5xULN.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Dose Reductions</title>
        <description>Number of participants with dose reductions due to any reason is presented.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Dose Reductions</title>
          <description>Number of participants with dose reductions due to any reason is presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Any Dose Interruptions or Delays</title>
        <description>Number of participants with any dose interruptions/ delays is presented.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Any Dose Interruptions or Delays</title>
          <description>Number of participants with any dose interruptions/ delays is presented.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="13"/>
                    <measurement group_id="O15" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters</title>
        <description>Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, prothrombin international normalized ratio (Pro. INR), albumin, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, triglycerides, alkaline phosphatase (ALP). Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters</title>
          <description>Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, prothrombin international normalized ratio (Pro. INR), albumin, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, triglycerides, alkaline phosphatase (ALP). Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="15"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pro.INR, n=0,1,1,5,1,3,4,16,3,4,0,6,5,11,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="11"/>
                    <count group_id="O15" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, n=1,1,1,5,1,4,8,18,3,8,1,7,7,15,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="12"/>
                    <measurement group_id="O15" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Ionized, n=1,1,1,4,1,4,7,17,3,8,1,7,7,15,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol,n=1,1,1,4,1,4,3,17,3,6,1,7,6,10,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="10"/>
                    <count group_id="O15" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, n=1,1,1,2,1,4,8,18,3,7,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, n=1,1,1,5,1,4,6,18,3,8,1,7,6,15,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, n=1,1,1,5,1,4,7,18,3,8,1,7,6,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium,n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="9"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, n=1,1,1,4,1,4,3,17,3,6,1,7,6,10,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="10"/>
                    <count group_id="O15" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Grade Change From Baseline in Hematology Parameters</title>
        <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Grade Change From Baseline in Hematology Parameters</title>
          <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="9"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, n=1,1,0,5,1,4,7,18,3,8,1,7,7,15,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="10"/>
                    <measurement group_id="O15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, n=1,1,0,5,1,4,7,18,3,8,1,7,7,15,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="11"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="9"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method</title>
        <description>Urine samples were collected to assess glucose, ketones, occult blood, urine protein, and monoclonal protein (monoclonal pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method</title>
          <description>Urine samples were collected to assess glucose, ketones, occult blood, urine protein, and monoclonal protein (monoclonal pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, n=1,1,1,4,1,4,4,15, 3,5,0,3,5,8,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, n=1,1,1,4,1,4,4,13,3,5,1,6,5,11,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="13"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="11"/>
                    <count group_id="O15" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, n=1,1,1,4,1,4,5,14,3,7,1,6,5,11,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="14"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="11"/>
                    <count group_id="O15" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, n=1,1,1,4,1,4,2,12,1,5,0,3,4,7,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="12"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="4"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monoclonal pro, n=0,0,0,0,0,1,0,0,2,0,0,0,0,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature</title>
        <description>Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low &lt;60 beats per minute [bpm] and high &gt;100 bpm); For body temperature (&lt;=35 degrees Celsius or &gt;=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category. Participants were counted twice if the participant had values that changed &quot;To Low&quot; and &quot;To High&quot;, so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature</title>
          <description>Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low &lt;60 beats per minute [bpm] and high &gt;100 bpm); For body temperature (&lt;=35 degrees Celsius or &gt;=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category. Participants were counted twice if the participant had values that changed &quot;To Low&quot; and &quot;To High&quot;, so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse rate, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate, To Normal or No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, To High,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="8"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (&lt;=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (&gt;=160 mmHg). For DBP: Grade 0 (&lt;=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (&gt;=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (&lt;=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (&gt;=160 mmHg). For DBP: Grade 0 (&lt;=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (&gt;=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)</title>
        <description>12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)</title>
          <description>12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-Clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal-Not Clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="12"/>
                    <measurement group_id="O15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Objective Response Rate (ORR) (MDS Cohort)</title>
        <description>ORR for MDS cohort is defined as the percentage of participants achieving Complete Response (CR), Marrow CR, CRp (as per CR but platelet count &lt;100 x 10^9 cells/Liter[L]), CRi (as per CR but platelet count &lt;100 x 10^9cells/L or neutrophil count &lt;1 x 10^9 cells/L), or Partial Response (PR) per response criteria. Complete response is defined as bone marrow &lt;=5% myeloblasts with normal maturation of all cell lines, with hemoglobin concentration of &gt;=11 grams per deciliter (g/dL), absolute neutrophil count &gt;=1 x 10^9 cells/L, platelet count &gt;=100x10^9 cells/L and 0% blasts in the peripheral blood. Marrow CR is defined as Bone marrow &lt;=5% myeloblasts and decrease by &gt;=50% over pre-treatment. Objective response rate was determined by the investigator according to international myeloma working group (IMWG) response criteria.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Objective Response Rate (ORR) (MDS Cohort)</title>
          <description>ORR for MDS cohort is defined as the percentage of participants achieving Complete Response (CR), Marrow CR, CRp (as per CR but platelet count &lt;100 x 10^9 cells/Liter[L]), CRi (as per CR but platelet count &lt;100 x 10^9cells/L or neutrophil count &lt;1 x 10^9 cells/L), or Partial Response (PR) per response criteria. Complete response is defined as bone marrow &lt;=5% myeloblasts with normal maturation of all cell lines, with hemoglobin concentration of &gt;=11 grams per deciliter (g/dL), absolute neutrophil count &gt;=1 x 10^9 cells/L, platelet count &gt;=100x10^9 cells/L and 0% blasts in the peripheral blood. Marrow CR is defined as Bone marrow &lt;=5% myeloblasts and decrease by &gt;=50% over pre-treatment. Objective response rate was determined by the investigator according to international myeloma working group (IMWG) response criteria.</description>
          <population>All Treated Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="7.3" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Objective Response Rate Lasting at Least 4 Months (ORR4) (CTCL Cohorts)</title>
        <description>ORR4 for CTCL cohorts is defined as the percentage of participants that have achieved a CR or PR lasting at least 4 months per global response criteria and the modified severity weighted assessment tool (mSWAT). ORR4 and 95% exact confidence interval is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Objective Response Rate Lasting at Least 4 Months (ORR4) (CTCL Cohorts)</title>
          <description>ORR4 for CTCL cohorts is defined as the percentage of participants that have achieved a CR or PR lasting at least 4 months per global response criteria and the modified severity weighted assessment tool (mSWAT). ORR4 and 95% exact confidence interval is presented.</description>
          <population>All Treated Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="41"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Overall Response Rate (ORR)- Investigator Assessment</title>
        <description>ORR is defined as the percentage of participants achieving stringent complete response (sCR), very good partial response (VGPR), partial response (PR) or minimal response (MR) for multiple myeloma (MM); CR or PR for Non-Hodgkin's Lymphoma (NHL); CR, CRp, CRi or PR for Acute Myeloid Leukemia (AML); CR, MR or PR for Myelodysplastic Syndrome (MDS) using the International Working Group (IWG) response criteria and IWG response criteria in myelodysplasia.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Overall Response Rate (ORR)- Investigator Assessment</title>
          <description>ORR is defined as the percentage of participants achieving stringent complete response (sCR), very good partial response (VGPR), partial response (PR) or minimal response (MR) for multiple myeloma (MM); CR or PR for Non-Hodgkin's Lymphoma (NHL); CR, CRp, CRi or PR for Acute Myeloid Leukemia (AML); CR, MR or PR for Myelodysplastic Syndrome (MDS) using the International Working Group (IWG) response criteria and IWG response criteria in myelodysplasia.</description>
          <population>All Treated Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="97.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="97.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="97.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="52.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="97.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="25" lower_limit="3.2" upper_limit="65.1"/>
                    <measurement group_id="O8" value="6" lower_limit="0.1" upper_limit="27.3"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O10" value="0" lower_limit="0" upper_limit="36.9"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="97.5"/>
                    <measurement group_id="O12" value="14" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O13" value="29" lower_limit="3.7" upper_limit="71.0"/>
                    <measurement group_id="O14" value="13" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O15" value="17" lower_limit="0.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0-24]) and AUC Extrapolated to Infinity (AUC[0-inf]) of GSK525762 Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population consisted of all participants in the All Treated Population for whom a PK sample was obtained and analyzed. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0-24]) and AUC Extrapolated to Infinity (AUC[0-inf]) of GSK525762 Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population consisted of all participants in the All Treated Population for whom a PK sample was obtained and analyzed. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24), n=1,1,1,5,1,4,8,18,3,8,1,6,7,16, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460.48" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O2" value="1024.49" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="2881.41" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="2146.54" spread="31.68"/>
                    <measurement group_id="O5" value="3317.10" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="2510.55" spread="71.29"/>
                    <measurement group_id="O7" value="6424.74" spread="22.42"/>
                    <measurement group_id="O8" value="5918.90" spread="52.85"/>
                    <measurement group_id="O9" value="3695.32" spread="62.01"/>
                    <measurement group_id="O10" value="7980.72" spread="45.28"/>
                    <measurement group_id="O11" value="5944.52" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="8394.69" spread="34.31"/>
                    <measurement group_id="O13" value="5017.96" spread="44.17"/>
                    <measurement group_id="O14" value="13520.57" spread="46.29"/>
                    <measurement group_id="O15" value="13688.54" spread="43.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-inf), n=1,1,1,5,1,4,7,17,3,8,1,5,7,16,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.81" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="1092.28" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="3054.11" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="2217.32" spread="32.55"/>
                    <measurement group_id="O5" value="3465.49" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="2546.49" spread="72.05"/>
                    <measurement group_id="O7" value="6951.06" spread="25.12"/>
                    <measurement group_id="O8" value="6214.97" spread="60.67"/>
                    <measurement group_id="O9" value="3874.05" spread="63.27"/>
                    <measurement group_id="O10" value="8248.45" spread="47.87"/>
                    <measurement group_id="O11" value="6032.36" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="9734.83" spread="29.60"/>
                    <measurement group_id="O13" value="5114.61" spread="44.76"/>
                    <measurement group_id="O14" value="14635.17" spread="52.35"/>
                    <measurement group_id="O15" value="17021.44" spread="35.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: AUC(0-24) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK525762 Following Repeat Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. AUC(0-24) represents AUC(0-tau) for repeat dose.</description>
        <time_frame>Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC(0-24) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK525762 Following Repeat Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. AUC(0-24) represents AUC(0-tau) for repeat dose.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.71" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="656.93" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="1855.07" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="1908.18" spread="27.53"/>
                    <measurement group_id="O5" value="2490.25" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="1702.37" spread="58.17"/>
                    <measurement group_id="O7" value="6271.43" spread="38.76"/>
                    <measurement group_id="O8" value="3576.49" spread="30.59"/>
                    <measurement group_id="O9" value="931.02" spread="53.64"/>
                    <measurement group_id="O10" value="5883.76" spread="48.48"/>
                    <measurement group_id="O11" value="5188.25" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="6892.57" spread="71.96"/>
                    <measurement group_id="O13" value="2994.24" spread="37.27"/>
                    <measurement group_id="O14" value="9440.98" spread="84.11"/>
                    <measurement group_id="O15" value="5296.46" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tau)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.71" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="656.93" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="1855.07" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="1908.18" spread="27.53"/>
                    <measurement group_id="O5" value="2490.25" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="1702.37" spread="58.17"/>
                    <measurement group_id="O7" value="6271.43" spread="38.76"/>
                    <measurement group_id="O8" value="3576.49" spread="30.59"/>
                    <measurement group_id="O9" value="931.02" spread="53.64"/>
                    <measurement group_id="O10" value="5883.76" spread="48.48"/>
                    <measurement group_id="O11" value="5188.25" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="6892.57" spread="71.96"/>
                    <measurement group_id="O13" value="2994.24" spread="37.27"/>
                    <measurement group_id="O14" value="9440.98" spread="84.11"/>
                    <measurement group_id="O15" value="5296.46" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Maximum Observed Concentration (Cmax) and Minimum Plasma Concentration (Cmin) of GSK525762 Following Single Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Observed Concentration (Cmax) and Minimum Plasma Concentration (Cmin) of GSK525762 Following Single Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.56" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="116.69" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="559.14" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="442.77" spread="31.83"/>
                    <measurement group_id="O5" value="513.03" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="660.79" spread="71.94"/>
                    <measurement group_id="O7" value="853.03" spread="31.1"/>
                    <measurement group_id="O8" value="1158.66" spread="28.58"/>
                    <measurement group_id="O9" value="813.87" spread="27.91"/>
                    <measurement group_id="O10" value="1728.80" spread="35.37"/>
                    <measurement group_id="O11" value="1248.10" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="1444.42" spread="29.92"/>
                    <measurement group_id="O13" value="1073.51" spread="38.46"/>
                    <measurement group_id="O14" value="2335.99" spread="23.05"/>
                    <measurement group_id="O15" value="1793.39" spread="42.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="27.86" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="20.62" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="7.55" spread="73.07"/>
                    <measurement group_id="O5" value="21.20" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="13.25" spread="71.79"/>
                    <measurement group_id="O7" value="107.30" spread="68.40"/>
                    <measurement group_id="O8" value="50.49" spread="139.83"/>
                    <measurement group_id="O9" value="29.39" spread="47.67"/>
                    <measurement group_id="O10" value="37.92" spread="80.33"/>
                    <measurement group_id="O11" value="129.76" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="71.43" spread="112.42"/>
                    <measurement group_id="O13" value="27.89" spread="115.67"/>
                    <measurement group_id="O14" value="89.96" spread="112.80"/>
                    <measurement group_id="O15" value="138.75" spread="111.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Cmax and Cmin of GSK525762 Following Repeat Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Cmax and Cmin of GSK525762 Following Repeat Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.86" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="118.59" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="550.01" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="387.66" spread="52.41"/>
                    <measurement group_id="O5" value="557.60" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="566.59" spread="57.75"/>
                    <measurement group_id="O7" value="1070.32" spread="37.26"/>
                    <measurement group_id="O8" value="1179.42" spread="28.10"/>
                    <measurement group_id="O9" value="512.78" spread="48.37"/>
                    <measurement group_id="O10" value="1384.46" spread="35.35"/>
                    <measurement group_id="O11" value="1752.86" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="1314.21" spread="58.58"/>
                    <measurement group_id="O13" value="725.29" spread="46.79"/>
                    <measurement group_id="O14" value="1587.25" spread="50.83"/>
                    <measurement group_id="O15" value="921.35" spread="52.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="5.03" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="3.92" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="7.72" spread="103.48"/>
                    <measurement group_id="O5" value="8.66" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="2.36" spread="84.21"/>
                    <measurement group_id="O7" value="57.75" spread="82.69"/>
                    <measurement group_id="O8" value="7.03" spread="51.10"/>
                    <measurement group_id="O9" value="1.63" spread="141.42"/>
                    <measurement group_id="O10" value="14.00" spread="112.58"/>
                    <measurement group_id="O11" value="21.02" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="50.89" spread="123.69"/>
                    <measurement group_id="O13" value="4.64" spread="73.29"/>
                    <measurement group_id="O14" value="55.63" spread="163.06"/>
                    <measurement group_id="O15" value="14.96" spread="64.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Trough Concentration (Ctau) of GSK525762 Following Repeat Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 2 Day 7: Pre-dose on Days 4, 6 and 7</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Trough Concentration (Ctau) of GSK525762 Following Repeat Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="3.90" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="3.76" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="4.88" spread="78.94"/>
                    <measurement group_id="O5" value="8.12" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="2.26" spread="114.63"/>
                    <measurement group_id="O7" value="32.85" spread="88.47"/>
                    <measurement group_id="O8" value="5.99" spread="41.92"/>
                    <measurement group_id="O9" value="0.03" spread="128.56"/>
                    <measurement group_id="O10" value="13.21" spread="102.35"/>
                    <measurement group_id="O11" value="2.08" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="15.77" spread="123.78"/>
                    <measurement group_id="O13" value="2.25" spread="92.05"/>
                    <measurement group_id="O14" value="42.18" spread="139.74"/>
                    <measurement group_id="O15" value="14.34" spread="68.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time of Maximum Concentration (Tmax) of GSK525762 Following Single Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time of Maximum Concentration (Tmax) of GSK525762 Following Single Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O2" value="2.00" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O3" value="1.00" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O4" value="1.00" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O5" value="1.00" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O6" value="0.78" lower_limit="0.4" upper_limit="2.0"/>
                    <measurement group_id="O7" value="1.56" lower_limit="0.3" upper_limit="2.1"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.3" upper_limit="4.1"/>
                    <measurement group_id="O9" value="1.00" lower_limit="0.5" upper_limit="2.2"/>
                    <measurement group_id="O10" value="0.86" lower_limit="0.5" upper_limit="2.1"/>
                    <measurement group_id="O11" value="1.28" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O12" value="1.03" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O13" value="1.00" lower_limit="0.3" upper_limit="1.2"/>
                    <measurement group_id="O14" value="0.92" lower_limit="0.3" upper_limit="4.0"/>
                    <measurement group_id="O15" value="1.58" lower_limit="0.2" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax of GSK525762 Following Repeat Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax of GSK525762 Following Repeat Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O3" value="0.83" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O4" value="1.26" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O5" value="0.50" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O6" value="0.78" lower_limit="0.5" upper_limit="1.2"/>
                    <measurement group_id="O7" value="0.58" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O8" value="0.50" lower_limit="0.3" upper_limit="2.0"/>
                    <measurement group_id="O9" value="0.63" lower_limit="0.3" upper_limit="1.0"/>
                    <measurement group_id="O10" value="0.60" lower_limit="0.3" upper_limit="4.0"/>
                    <measurement group_id="O11" value="0.50" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O12" value="0.98" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O13" value="1.06" lower_limit="0.6" upper_limit="2.0"/>
                    <measurement group_id="O14" value="2.00" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O15" value="2.33" lower_limit="0.5" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Terminal Half Life (T1/2) of GSK525762 Following Single Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Terminal Half Life (T1/2) of GSK525762 Following Single Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O2" value="5.75" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O3" value="6.27" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O4" value="4.55" lower_limit="1.4" upper_limit="6.4"/>
                    <measurement group_id="O5" value="5.10" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O6" value="4.07" lower_limit="3.5" upper_limit="4.6"/>
                    <measurement group_id="O7" value="6.48" lower_limit="5.2" upper_limit="10.3"/>
                    <measurement group_id="O8" value="3.96" lower_limit="2.9" upper_limit="9.3"/>
                    <measurement group_id="O9" value="5.55" lower_limit="1.4" upper_limit="8.1"/>
                    <measurement group_id="O10" value="4.57" lower_limit="3.3" upper_limit="6.3"/>
                    <measurement group_id="O11" value="4.15" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O12" value="4.75" lower_limit="4.1" upper_limit="7.4"/>
                    <measurement group_id="O13" value="4.06" lower_limit="3.0" upper_limit="5.8"/>
                    <measurement group_id="O14" value="5.66" lower_limit="1.9" upper_limit="9.7"/>
                    <measurement group_id="O15" value="6.53" lower_limit="4.7" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: T1/2 of GSK525762 Following Repeat Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: T1/2 of GSK525762 Following Repeat Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O2" value="5.64" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O3" value="4.70" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O4" value="4.15" lower_limit="2.9" upper_limit="6.4"/>
                    <measurement group_id="O5" value="4.39" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O6" value="4.39" lower_limit="3.2" upper_limit="5.8"/>
                    <measurement group_id="O7" value="6.48" lower_limit="3.4" upper_limit="7.8"/>
                    <measurement group_id="O8" value="3.51" lower_limit="3.0" upper_limit="5.3"/>
                    <measurement group_id="O9" value="1.96" lower_limit="1.7" upper_limit="2.3"/>
                    <measurement group_id="O10" value="3.97" lower_limit="3.1" upper_limit="5.3"/>
                    <measurement group_id="O11" value="2.54" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O12" value="4.98" lower_limit="2.4" upper_limit="5.9"/>
                    <measurement group_id="O13" value="3.22" lower_limit="2.2" upper_limit="3.7"/>
                    <measurement group_id="O14" value="5.51" lower_limit="3.2" upper_limit="8.6"/>
                    <measurement group_id="O15" value="4.09" lower_limit="3.8" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time Invariance (RS) of GSK525762</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time Invariance (RS) of GSK525762</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="0.60" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="0.61" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="0.71" spread="35.82"/>
                    <measurement group_id="O5" value="0.72" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="0.67" spread="18.60"/>
                    <measurement group_id="O7" value="0.98" spread="11.73"/>
                    <measurement group_id="O8" value="0.65" spread="31.37"/>
                    <measurement group_id="O9" value="0.32" spread="53.56"/>
                    <measurement group_id="O10" value="0.78" spread="46.56"/>
                    <measurement group_id="O11" value="0.86" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="0.91" spread="36.22"/>
                    <measurement group_id="O13" value="0.74" spread="19.36"/>
                    <measurement group_id="O14" value="0.76" spread="84.74"/>
                    <measurement group_id="O15" value="0.54" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Accumulation Ratio (RO) of GSK525762</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Accumulation Ratio (RO) of GSK525762</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O2" value="0.64" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O3" value="0.64" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O4" value="0.74" spread="36.67"/>
                    <measurement group_id="O5" value="0.75" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O6" value="0.68" spread="17.66"/>
                    <measurement group_id="O7" value="1.06" spread="13.47"/>
                    <measurement group_id="O8" value="0.67" spread="29.24"/>
                    <measurement group_id="O9" value="0.33" spread="47.64"/>
                    <measurement group_id="O10" value="0.81" spread="45.70"/>
                    <measurement group_id="O11" value="0.87" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O12" value="1.01" spread="33.69"/>
                    <measurement group_id="O13" value="0.75" spread="20.27"/>
                    <measurement group_id="O14" value="0.81" spread="82.45"/>
                    <measurement group_id="O15" value="0.71" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Clearance (CL/F) of GSK525762 After Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QC CTCL arm for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Clearance (CL/F) of GSK525762 After Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QC CTCL arm for this outcome measure.</population>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.80" spread="3.39"/>
                    <measurement group_id="O2" value="7.98" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Clearance (CL/F) of GSK525762 After Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Clearance (CL/F) of GSK525762 After Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.80" spread="3.39"/>
                    <measurement group_id="O2" value="9.33" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QC CTCL arm for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QC CTCL arm for this outcome measure.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="19.50"/>
                    <measurement group_id="O2" value="47.9" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="19.50"/>
                    <measurement group_id="O2" value="45.8" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: AUC(0-24) and AUC[0-inf] of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
        <description>Plasma samples for PK analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles). Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC(0-24) and AUC[0-inf] of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
          <description>Plasma samples for PK analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles). Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="15"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24), n=0,0,0,5,0,1,0,15, 2,8,0,0,6,15,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1368.11" spread="31.39"/>
                    <measurement group_id="O6" value="1891.48" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="3048.33" spread="22.85"/>
                    <measurement group_id="O9" value="3297.95" spread="68.31"/>
                    <measurement group_id="O10" value="3174.42" spread="40.63"/>
                    <measurement group_id="O13" value="3432.89" spread="39.76"/>
                    <measurement group_id="O14" value="2901.79" spread="52.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-inf), n=0,0,0,5,0,1,0,10, 2,7,0,0,6,7,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1691.75" spread="28.96"/>
                    <measurement group_id="O6" value="2013.33" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="3684.96" spread="28.50"/>
                    <measurement group_id="O9" value="4499.65" spread="72.79"/>
                    <measurement group_id="O10" value="4003.48" spread="42.09"/>
                    <measurement group_id="O13" value="3908.15" spread="41.20"/>
                    <measurement group_id="O14" value="4714.85" spread="48.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: AUC(0-24) and AUC(0-tau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762. AUC(0-tau) is AUC(0-24) for repeat dose.</description>
        <time_frame>Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC(0-24) and AUC(0-tau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762. AUC(0-tau) is AUC(0-24) for repeat dose.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="10"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1517.96" spread="33.88"/>
                    <measurement group_id="O6" value="1922.77" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="4870.28" spread="46.15"/>
                    <measurement group_id="O9" value="3838.35" spread="37.18"/>
                    <measurement group_id="O10" value="5312.66" spread="45.30"/>
                    <measurement group_id="O13" value="3379.85" spread="44.24"/>
                    <measurement group_id="O14" value="8534.92" spread="43.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tau)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1517.96" spread="33.88"/>
                    <measurement group_id="O6" value="1922.77" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="4870.28" spread="46.15"/>
                    <measurement group_id="O9" value="3838.35" spread="37.18"/>
                    <measurement group_id="O10" value="5312.66" spread="45.30"/>
                    <measurement group_id="O13" value="3379.85" spread="44.24"/>
                    <measurement group_id="O14" value="8534.92" spread="43.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles). Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles). Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, n=0,0,0,5,0,1, 0,15,3,8,0,0,7,16,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="109.45" spread="45.38"/>
                    <measurement group_id="O6" value="246.12" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="239.98" spread="26.75"/>
                    <measurement group_id="O9" value="361.30" spread="54.77"/>
                    <measurement group_id="O10" value="251.73" spread="49.71"/>
                    <measurement group_id="O13" value="325.42" spread="47.17"/>
                    <measurement group_id="O14" value="201.02" spread="56.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, n=0,0,0,2,0,1, 0,14,3,7,0,0,6,13,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="14"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="13"/>
                    <count group_id="O15" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2.47" spread="4.29"/>
                    <measurement group_id="O6" value="66.39" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="18.17" spread="116.63"/>
                    <measurement group_id="O9" value="10.83" spread="161.52"/>
                    <measurement group_id="O10" value="18.45" spread="71.98"/>
                    <measurement group_id="O13" value="12.66" spread="108.08"/>
                    <measurement group_id="O14" value="14.17" spread="99.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="121.83" spread="26.75"/>
                    <measurement group_id="O6" value="282.72" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="453.89" spread="34.07"/>
                    <measurement group_id="O9" value="500.61" spread="22.83"/>
                    <measurement group_id="O10" value="445.47" spread="52.02"/>
                    <measurement group_id="O13" value="370.67" spread="35.23"/>
                    <measurement group_id="O14" value="557.92" spread="31.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="27.14" spread="28.38"/>
                    <measurement group_id="O6" value="15.18" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="66.49" spread="81.56"/>
                    <measurement group_id="O9" value="40.88" spread="45.39"/>
                    <measurement group_id="O10" value="73.60" spread="88.34"/>
                    <measurement group_id="O13" value="38.71" spread="56.34"/>
                    <measurement group_id="O14" value="116.62" spread="74.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Trough Concentration (Ctau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 2 Day 7: Pre-dose on Days 4, 6 and 7</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Trough Concentration (Ctau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="10"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="22.48" spread="36.13"/>
                    <measurement group_id="O6" value="13.26" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="64.57" spread="77.46"/>
                    <measurement group_id="O9" value="40.42" spread="43.96"/>
                    <measurement group_id="O10" value="76.23" spread="62.65"/>
                    <measurement group_id="O13" value="28.29" spread="94.01"/>
                    <measurement group_id="O14" value="178.76" spread="69.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1.92" lower_limit="0.9" upper_limit="4.1"/>
                    <measurement group_id="O6" value="0.58" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O8" value="2.10" lower_limit="0.5" upper_limit="8.0"/>
                    <measurement group_id="O9" value="4.00" lower_limit="2.0" upper_limit="4.2"/>
                    <measurement group_id="O10" value="3.15" lower_limit="1.2" upper_limit="4.1"/>
                    <measurement group_id="O13" value="2.08" lower_limit="0.3" upper_limit="4.2"/>
                    <measurement group_id="O14" value="4.03" lower_limit="2.0" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2.48" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="0.60" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual Tmax for this single participant.</measurement>
                    <measurement group_id="O8" value="1.03" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O9" value="1.00" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O10" value="2.05" lower_limit="0.6" upper_limit="4.0"/>
                    <measurement group_id="O13" value="2.02" lower_limit="1.2" upper_limit="4.1"/>
                    <measurement group_id="O14" value="4.00" lower_limit="0.9" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="9.90" lower_limit="5.2" upper_limit="13.4"/>
                    <measurement group_id="O6" value="5.83" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.</measurement>
                    <measurement group_id="O8" value="8.66" lower_limit="6.7" upper_limit="14.1"/>
                    <measurement group_id="O9" value="12.72" lower_limit="11.5" upper_limit="13.9"/>
                    <measurement group_id="O10" value="8.31" lower_limit="5.4" upper_limit="15.7"/>
                    <measurement group_id="O13" value="7.16" lower_limit="6.3" upper_limit="9.1"/>
                    <measurement group_id="O14" value="9.23" lower_limit="5.1" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="8"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="8.24" lower_limit="7.7" upper_limit="10.0"/>
                    <measurement group_id="O6" value="6.19" lower_limit="NA" upper_limit="NA">Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant</measurement>
                    <measurement group_id="O8" value="7.97" lower_limit="5.7" upper_limit="12.4"/>
                    <measurement group_id="O9" value="7.39" lower_limit="7.3" upper_limit="7.5"/>
                    <measurement group_id="O10" value="8.00" lower_limit="5.8" upper_limit="10.5"/>
                    <measurement group_id="O13" value="6.72" lower_limit="4.0" upper_limit="8.7"/>
                    <measurement group_id="O14" value="11.77" lower_limit="6.9" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time Invariance (RS) of GSK3529246 (Active Metabolite)</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time Invariance (RS) of GSK3529246 (Active Metabolite)</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.92" spread="25.58"/>
                    <measurement group_id="O6" value="0.96" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="1.18" spread="32.33"/>
                    <measurement group_id="O9" value="0.63" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O10" value="1.20" spread="13.74"/>
                    <measurement group_id="O13" value="1.06" spread="9.48"/>
                    <measurement group_id="O14" value="1.87" spread="57.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Accumulation Ratio (RO) of GSK3529246 (Active Metabolite)</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Accumulation Ratio (RO) of GSK3529246 (Active Metabolite)</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed. Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="9"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1.18" spread="25.71"/>
                    <measurement group_id="O6" value="1.02" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O8" value="1.61" spread="31.61"/>
                    <measurement group_id="O9" value="0.90" spread="NA">Geometric coefficient of variation could not be calculated for a single participant</measurement>
                    <measurement group_id="O10" value="1.56" spread="26.04"/>
                    <measurement group_id="O13" value="1.20" spread="11.50"/>
                    <measurement group_id="O14" value="3.22" spread="59.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. PK parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QC CTCL.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. PK parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QC CTCL.</population>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="7.71"/>
                    <measurement group_id="O2" value="15.8" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="7.26"/>
                    <measurement group_id="O2" value="14.6" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QD CTCL.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N&quot; of 75 mg arm within this outcome measure is greater than overall &quot;N&quot; for 75 mg QD MDS &amp; N=0 for 80 mg QD CTCL.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="37.1"/>
                    <measurement group_id="O2" value="71.5" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
        <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
        <time_frame>Week 3 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose</time_frame>
        <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration</title>
          <description>Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.</description>
          <population>PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to &quot;N=0&quot; for 80 mg QD arm within this outcome measure.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="37.1"/>
                    <measurement group_id="O2" value="63.4" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in Skindex-29 Domain Scores (Emotional, Functioning and Symptoms Score) for CTCL Cohort</title>
        <description>The effects of treatment on disease-related symptoms/quality of life was assessed using the Skindex-29 Questionnaire, which inquires about how often (Never, Rarely, Sometimes, Often, All the time) during the previous 4 weeks the participant experienced the effect described in each of 29 items divided into 3 domains: Emotional (10 items), Symptoms (7 items) and Functioning (12 items). Responses to each item are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex-29 scores were reported as three individual domain scale scores; a scale score is the mean of a participant's responses to items in a given domain. Each domain score ranges from 0 (no effect) to 100 (effect experienced all the time), higher score implies higher impact of skin disease. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is defined is post-dose visit value minus Baseline.</description>
        <time_frame>Baseline (pre-dose Week1 Day1) and Week 3, Week 7, Week 10, Week 16 and Week 24</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Skindex-29 Domain Scores (Emotional, Functioning and Symptoms Score) for CTCL Cohort</title>
          <description>The effects of treatment on disease-related symptoms/quality of life was assessed using the Skindex-29 Questionnaire, which inquires about how often (Never, Rarely, Sometimes, Often, All the time) during the previous 4 weeks the participant experienced the effect described in each of 29 items divided into 3 domains: Emotional (10 items), Symptoms (7 items) and Functioning (12 items). Responses to each item are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex-29 scores were reported as three individual domain scale scores; a scale score is the mean of a participant's responses to items in a given domain. Each domain score ranges from 0 (no effect) to 100 (effect experienced all the time), higher score implies higher impact of skin disease. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is defined is post-dose visit value minus Baseline.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional score, Week 3, n=6,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="15.221"/>
                    <measurement group_id="O2" value="9.17" spread="NA">Standard deviation could not be calculated for a single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional score, Week 7, n=5,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.50" spread="22.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional score, Week 10, n=3,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.17" spread="26.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional score, Week 16, n=3,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.00" spread="10.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional score, Week 24, n=2,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.75" spread="1.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functioning score, Week 3, n=6,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="7.742"/>
                    <measurement group_id="O2" value="30.87" spread="NA">Standard deviation could not be calculated for a single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functioning score, Week 7, n=5,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.37" spread="23.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functioning score, Week 10, n=3,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.67" spread="27.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functioning score, Week 16, n=3,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.45" spread="9.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functioning score, Week 24, n=2,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.84" spread="11.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms score, Week 3, n=6,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="24.055"/>
                    <measurement group_id="O2" value="12.50" spread="NA">Standard deviation could not be calculated for a single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms score, Week 7, n=5,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="18.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms score, Week 10, n=3,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.76" spread="20.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms score, Week 16, n=3,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="19.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms score, Week 24, n=2,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.29" spread="10.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Non-serious AEs and SAEs and AELDs</title>
        <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Non-serious AEs and SAEs and AELDs</title>
          <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AELD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Dose Reductions</title>
        <description>Number of participants with dose reductions due to any reason is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Dose Reductions</title>
          <description>Number of participants with dose reductions due to any reason is presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Dose Interruptions/Delays</title>
        <description>Number of participants with any dose interruptions or delays is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Dose Interruptions/Delays</title>
          <description>Number of participants with any dose interruptions or delays is presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters</title>
        <description>Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, Prothrombin international normalized ratio (Pro. INR), albumin, amylase, ALT, AST, bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, Triglycerides, ALP. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters</title>
          <description>Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, Prothrombin international normalized ratio (Pro. INR), albumin, amylase, ALT, AST, bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, Triglycerides, ALP. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pro.INR, n=4,13,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase, n=7,15,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, n=7,15,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Ionized, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, n=7,15,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, n=5,11,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, n=7,13,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, n=7,15,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, n=7,16,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Grade Change From Baseline in Hematology Parameters</title>
        <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Grade Change From Baseline in Hematology Parameters</title>
          <description>Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method</title>
        <description>Urine samples were collected to assess glucose, ketones, occult blood, urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method</title>
          <description>Urine samples were collected to assess glucose, ketones, occult blood, urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.</description>
          <population>All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, n=5,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, n=7,12,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, n=7,8,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, n=6,11,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature</title>
        <description>Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low &lt;60 beats per minute [bpm] and high &gt;100 bpm); For body temperature (&lt;=35 degrees Celsius or &gt;=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category. Participants were counted twice if the participant had values that changed &quot;To Low&quot; and &quot;To High&quot;, so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature</title>
          <description>Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low &lt;60 beats per minute [bpm] and high &gt;100 bpm); For body temperature (&lt;=35 degrees Celsius or &gt;=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category. Participants were counted twice if the participant had values that changed &quot;To Low&quot; and &quot;To High&quot;, so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse rate, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate, To Normal or No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: DBP and SBP</title>
        <description>DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (&lt;=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (&gt;=160 mmHg). For DBP: Grade 0 (&lt;=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (&gt;=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: DBP and SBP</title>
          <description>DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (&lt;=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (&gt;=160 mmHg). For DBP: Grade 0 (&lt;=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (&gt;=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)</title>
        <description>12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)</title>
          <description>12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-Clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal-Not Clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Progression Free Survival (PFS)</title>
        <description>PFS defined as interval of time(in months) between date of first dose &amp; earlier of date of disease progression &amp; date of death due to any cause.Progression is participants(pt's)with MDS &amp; with &lt;5% blasts:&gt;=50% increase in blasts to&gt;5% blasts/pt's with 5-10% blasts:&gt;=50% increase to &gt;10% blasts, for pt's with 10-20% blasts:&gt;=50% increase to &gt;20% blasts,for pt's with 20%-30% blasts:&gt;=50% increase to &gt;30% blasts, for CTCL progression is &gt;=25% increase in skin disease from Baseline/new tumors (T3[1 or more tumors(&gt;=1cm diameter]) in pt's with T1(Limited patches,papules&amp;/or plaques covering &lt;10% of the skin surface;may further stratify into T1a [patch only] versus T1b [plaque+-patch]),T2(Patches,papules/plaques covering &gt;=10% of skin surface;may further stratify into T2a[patch only]versus T2b [plaque+-patch]) orT4(Confluence of erythema covering &gt;=80% body surface area) only skin disease/loss of response in those with CR/PR, increase of skin score of &gt; sum of nadir +50% Baseline score.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Progression Free Survival (PFS)</title>
          <description>PFS defined as interval of time(in months) between date of first dose &amp; earlier of date of disease progression &amp; date of death due to any cause.Progression is participants(pt's)with MDS &amp; with &lt;5% blasts:&gt;=50% increase in blasts to&gt;5% blasts/pt's with 5-10% blasts:&gt;=50% increase to &gt;10% blasts, for pt's with 10-20% blasts:&gt;=50% increase to &gt;20% blasts,for pt's with 20%-30% blasts:&gt;=50% increase to &gt;30% blasts, for CTCL progression is &gt;=25% increase in skin disease from Baseline/new tumors (T3[1 or more tumors(&gt;=1cm diameter]) in pt's with T1(Limited patches,papules&amp;/or plaques covering &lt;10% of the skin surface;may further stratify into T1a [patch only] versus T1b [plaque+-patch]),T2(Patches,papules/plaques covering &gt;=10% of skin surface;may further stratify into T2a[patch only]versus T2b [plaque+-patch]) orT4(Confluence of erythema covering &gt;=80% body surface area) only skin disease/loss of response in those with CR/PR, increase of skin score of &gt; sum of nadir +50% Baseline score.</description>
          <population>All Treated Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" lower_limit="3.48" upper_limit="NA">Third quartile could not be calculated</measurement>
                    <measurement group_id="O2" value="2.00" lower_limit="1.45" upper_limit="3.48"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">No event occurred for single participant hence Median and Inter-quartile range could not be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Duration of Response (DOR)</title>
        <description>Duration of response is defined as the time from the first documented evidence response (CR or PR lasting 4 months for CTCL; and CR, marrow CR, CRp, Cri or PR for MDS) until the first documented disease progression or death due to any cause. Median and inter-quartile range (first quartile and third quartile) of duration of response are presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All treated Population. Only those participants with data available at the specified data points were analyzed. Participants with incomplete response rates were excluded from the analysis hence N=0 for 60 mg QD and 80 mg QD CTCL arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Duration of Response (DOR)</title>
          <description>Duration of response is defined as the time from the first documented evidence response (CR or PR lasting 4 months for CTCL; and CR, marrow CR, CRp, Cri or PR for MDS) until the first documented disease progression or death due to any cause. Median and inter-quartile range (first quartile and third quartile) of duration of response are presented.</description>
          <population>All treated Population. Only those participants with data available at the specified data points were analyzed. Participants with incomplete response rates were excluded from the analysis hence N=0 for 60 mg QD and 80 mg QD CTCL arms.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.29" lower_limit="3.29" upper_limit="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Overall Survival (OS)</title>
        <description>OS is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Overall Survival (OS)</title>
          <description>OS is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.</description>
          <population>All Treated Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and inter-quartile range was not reached.</measurement>
                    <measurement group_id="O2" value="5.85" lower_limit="1.46" upper_limit="16.10"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">No event occurred for single participant hence Median and Inter-quartile range could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Part 2: Time to Progression (TTP) for Participants With MM</title>
        <description>Time to Progression was planned to be analyzed.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time to Progression (TTP) for Participants With MM</title>
          <description>Time to Progression was planned to be analyzed.</description>
          <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Part 1: Changes in Cardiac QT Duration Corrected for Heart Rate by Fridericia's Formula (QTcF) and Other Safety Parameters in Relation to GSK525762 PK Concentrations</title>
        <description>Changes in QTcF and other safety parameters in relation to GSK525762 PK concentrations was planned to be analyzed.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Changes in Cardiac QT Duration Corrected for Heart Rate by Fridericia's Formula (QTcF) and Other Safety Parameters in Relation to GSK525762 PK Concentrations</title>
          <description>Changes in QTcF and other safety parameters in relation to GSK525762 PK concentrations was planned to be analyzed.</description>
          <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Part 1: Number of Participants With Dose /Exposure Markers Related Change in Molecular Markers in Tumor Tissue and/or Peripheral Blood Samples</title>
        <description>Number of participants with dose /exposure markers related change in molecular markers (e.g. gene transcription and/or expression of proteins regulated by Bromodomain [BRD] proteins) in tumor tissue and/or peripheral blood samples were planned to be analyzed.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Dose /Exposure Markers Related Change in Molecular Markers in Tumor Tissue and/or Peripheral Blood Samples</title>
          <description>Number of participants with dose /exposure markers related change in molecular markers (e.g. gene transcription and/or expression of proteins regulated by Bromodomain [BRD] proteins) in tumor tissue and/or peripheral blood samples were planned to be analyzed.</description>
          <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Part 2: Plasma Concentrations of GSK525762 in Relationship With Safety and Efficacy Parameters Derived From Pharmacokinetic/Pharmacodynamic (PK/PD) Model</title>
        <description>Plasma concentrations of GSK525762 in relationship with safety and efficacy parameters derived from PK/PD model was planned to be analyzed.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>PK Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Plasma Concentrations of GSK525762 in Relationship With Safety and Efficacy Parameters Derived From Pharmacokinetic/Pharmacodynamic (PK/PD) Model</title>
          <description>Plasma concentrations of GSK525762 in relationship with safety and efficacy parameters derived from PK/PD model was planned to be analyzed.</description>
          <population>PK Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Part 2: Number of Participants With Dose /Exposure Markers Related Change in Molecular Markers in Tumor Tissue and/or Peripheral Blood Samples</title>
        <description>Number of participants with dose /exposure markers related change in molecular markers (e.g. gene transcription and/or expression of proteins regulated by Bromodomain proteins) in tumor tissue and/or peripheral blood samples were planned to be analyzed.</description>
        <time_frame>Up to 36.4 weeks</time_frame>
        <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK525762 60 mg QD CTCL</title>
            <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK525762 75 mg QD MDS</title>
            <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK525762 80 mg QD CTCL</title>
            <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Dose /Exposure Markers Related Change in Molecular Markers in Tumor Tissue and/or Peripheral Blood Samples</title>
          <description>Number of participants with dose /exposure markers related change in molecular markers (e.g. gene transcription and/or expression of proteins regulated by Bromodomain proteins) in tumor tissue and/or peripheral blood samples were planned to be analyzed.</description>
          <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Part 1: Overall Survival (OS)</title>
        <description>Overall survival (defined as the interval of time in months between the date of first dose and the date of death due to any cause) was planned to be analyzed.</description>
        <time_frame>Up to 86.9 weeks</time_frame>
        <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK525762 5 mg QD</title>
            <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK525762 10 mg QD</title>
            <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK525762 20 mg QD</title>
            <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK525762 30 mg QD MM</title>
            <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK525762 40 mg QD</title>
            <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: GSK525762 40 mg QD MM</title>
            <description>Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: GSK525762 60 mg QD AML</title>
            <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: GSK525762 60 mg QD NHL</title>
            <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: GSK525762 60 mg QD MM</title>
            <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
          </group>
          <group group_id="O10">
            <title>Part 1: GSK525762 75 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
          </group>
          <group group_id="O11">
            <title>Part 1: GSK525762 80 mg QD</title>
            <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O12">
            <title>Part 1: GSK525762 80 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O13">
            <title>Part 1: GSK525762 80 mg QD NHL</title>
            <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
          </group>
          <group group_id="O14">
            <title>Part 1: GSK525762 100 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
          </group>
          <group group_id="O15">
            <title>Part 1: GSK525762 120 mg QD AML</title>
            <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Overall Survival (OS)</title>
          <description>Overall survival (defined as the interval of time in months between the date of first dose and the date of death due to any cause) was planned to be analyzed.</description>
          <population>All Treated Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality, non-serious and serious adverse events were collected from the start of study treatment until 28 days following discontinuation of study treatment (up to 86.9 weeks for Part 1 and up to 36.4 weeks for Part 2)</time_frame>
      <desc>All-cause mortality, non-serious AEs and SAEs were collected in All Treated population.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK525762 5 MG QD</title>
          <description>Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.</description>
        </group>
        <group group_id="E2">
          <title>GSK525762 10 MG QD</title>
          <description>Participants were administered once daily oral dose of 10 mg GSK525762.</description>
        </group>
        <group group_id="E3">
          <title>GSK525762 20 MG QD</title>
          <description>Participants were administered once daily oral dose of 20 mg GSK525762.</description>
        </group>
        <group group_id="E4">
          <title>GSK525762 30 MG QD MM</title>
          <description>Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.</description>
        </group>
        <group group_id="E5">
          <title>GSK525762 40 MG QD</title>
          <description>Participants were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="E6">
          <title>GSK525762 40 MG QD MM</title>
          <description>Participants with MM were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="E7">
          <title>GSK525762 60 MG QD AML</title>
          <description>Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 40 mg GSK525762.</description>
        </group>
        <group group_id="E8">
          <title>GSK525762 60 MG QD NHL</title>
          <description>Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="E9">
          <title>GSK525762 60 MG QD MM</title>
          <description>Participants with MM were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="E10">
          <title>GSK525762 75 MG QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 75 mg GSK525762.</description>
        </group>
        <group group_id="E11">
          <title>GSK525762 80 MG QD</title>
          <description>Participants were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="E12">
          <title>GSK525762 80 MG QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="E13">
          <title>GSK525762 80 MG QD NHL</title>
          <description>Participants with NHL were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
        <group group_id="E14">
          <title>GSK525762 100 MG QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 100 mg GSK525762.</description>
        </group>
        <group group_id="E15">
          <title>GSK525762 120 MG QD AML</title>
          <description>Participants with AML were administered once daily oral dose of 120 mg GSK525762.</description>
        </group>
        <group group_id="E16">
          <title>GSK525762 60 MG QD CTCL</title>
          <description>Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.</description>
        </group>
        <group group_id="E17">
          <title>GSK525762 75 MG QD MDS</title>
          <description>Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762.</description>
        </group>
        <group group_id="E18">
          <title>GSK525762 80 MG QD CTCL</title>
          <description>Participants CTCL were administered once daily oral dose of 80 mg GSK525762.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gingival hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" events="11" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Herpes simplex reactivation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mucormycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Starvation ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperammonaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E17" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="6" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" events="15" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="14" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" events="10" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E15" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="12" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="8" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="11" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="10" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="8" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E17" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

